Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Oyster Point Pharma, Inc. (OYST)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues [+] | 5.6 | 4.7 | 2.7 | 6.6 | 17.9 | 0.0 | 0.0 | 0.0 |
| Products | 5.6 | 4.7 | | | | | | |
| Revenue growth | -68.8% | | | | | | | |
| Cost of goods sold | 1.3 | 1.3 | 0.3 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 4.2 | 3.4 | 2.4 | 5.1 | 17.9 | 0.0 | 0.0 | 0.0 |
| Gross margin | 75.9% | 72.1% | 87.6% | 76.9% | 100.0% | | | |
| Selling, general and administrative [+] | 34.2 | 42.1 | 39.9 | 38.6 | 28.5 | 15.3 | 13.1 | 10.5 |
| Sales and marketing | 22.1 | 28.1 | 27.0 | 54.6 | 18.2 | 6.2 | 4.6 | 9.9 |
| General and administrative | 12.1 | 14.0 | 12.9 | -16.1 | 10.3 | 9.1 | 8.5 | 0.7 |
| Research and development | 3.9 | 4.7 | 4.7 | 5.5 | 6.2 | 6.7 | 5.8 | 11.7 |
| EBITDA [+] | -33.8 | -43.3 | -42.1 | -38.9 | -16.7 | -22.0 | -18.9 | -22.2 |
| EBITDA growth | 102.2% | 96.8% | 123.0% | 75.0% | 2.6% | 42.2% | 11.7% | 10.3% |
| EBITDA margin | -605.2% | -922.1% | -1558.3% | -589.6% | -93.3% | | | |
| Depreciation and amortization | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -33.9 | -43.4 | -42.2 | -38.9 | -16.8 | -22.0 | -18.9 | -22.2 |
| EBIT growth | 102.2% | 97.0% | 123.1% | 75.1% | 2.7% | 42.2% | 11.8% | 10.3% |
| EBIT margin | -606.6% | -924.5% | -1561.1% | -590.4% | -93.5% | | | |
| Interest expense | 3.5 | 3.2 | 3.1 | 2.6 | 1.1 | | | |
| Interest expense | 3.5 | 3.2 | 3.1 | 2.6 | 1.1 | | | |
| Other income (expense), net | 0.7 | -3.4 | -2.6 | -0.5 | 0.2 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -36.7 | -49.9 | -47.9 | -42.1 | -17.7 | -22.0 | -18.9 | -22.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -36.7 | -49.9 | -47.9 | -42.1 | -17.7 | -22.0 | -18.9 | -22.2 |
| Net margin | -657.3% | -1064.2% | -1771.2% | -637.7% | -98.5% | | | |
| |
| Basic EPS [+] | ($1.37) | ($1.87) | ($1.80) | ($1.62) | ($0.68) | ($0.85) | ($0.73) | ($0.92) |
| Growth | 101.8% | 120.4% | 146.5% | 75.3% | 7.4% | 28.4% | -5.7% | -78.6% |
| Diluted EPS [+] | ($1.37) | ($1.87) | ($1.80) | ($1.62) | ($0.68) | ($0.85) | ($0.73) | ($0.92) |
| Growth | 101.8% | 120.4% | 146.5% | 75.3% | 7.4% | 28.4% | -5.7% | -78.6% |
| |
| Shares outstanding (basic) [+] | 26.8 | 26.7 | 26.6 | 26.0 | 26.0 | 26.0 | 25.9 | 24.1 |
| Growth | 3.0% | 2.9% | 2.7% | 7.9% | 0.9% | 10.9% | 21.3% | 426.2% |
| Shares outstanding (diluted) [+] | 26.8 | 26.7 | 26.6 | 26.0 | 26.0 | 26.0 | 25.9 | 24.1 |
| Growth | 3.0% | 2.9% | 2.7% | 7.9% | 0.9% | 10.9% | 21.3% | 426.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|